D'Orazio & Associates’s NervGen Pharma NGEN Stock Holding History

D'Orazio & Associates’s Portfolio NGEN Stock Details NGEN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$37.7K	Buy	+10,000	New	+$43.3K	﹤0.01%	298

Other funds holding NGEN

PFG Investments Woodbury, New York $2.15B AUM 25.5% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

IWC

Integrated Wealth Concepts Waltham, Massachusetts $12.5B AUM 18.49% 1-Year Est. Return

VFIC

Valley Forge Investment Consultants Audubon, Pennsylvania $334M AUM 17.84% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

D'Orazio & Associates's NGEN Position: Q1 2026 in Review

D'Orazio & Associates opened a new position in NervGen Pharma (NGEN) in Q1 2026: 10,000 shares worth $37.7K. The stake represents ﹤0.01% of the portfolio and ranks #298 among its holdings.

45 funds tracked by Wall St. Rank hold NGEN as of Q1 2026.

D'Orazio & Associates held 10,000 shares of NervGen Pharma worth $37.7K as of Q1 2026.
NervGen Pharma was a new D'Orazio & Associates position in Q1 2026.
NervGen Pharma made up ﹤0.01% of D'Orazio & Associates's portfolio in Q1 2026, its #298 holding.
45 funds tracked by Wall St. Rank held NervGen Pharma as of Q1 2026.

Based on D'Orazio & Associates's 13F filing for Q1 2026, filed 7 May 2026.